What development phase is INFLUENZA B VIRUS, INACTIVATED NEURAMINIDASE in?

INFLUENZA B VIRUS, INACTIVATED NEURAMINIDASE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

INFLUENZA B VIRUS, INACTIVATED NEURAMINIDASE

FDA-approved approved Vaccine component Quality 0/100

The Influenza B Virus, Inactivated Neuraminidase is a marketed vaccine with a key composition patent expiring in 2028. The vaccine's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	INFLUENZA B VIRUS, INACTIVATED NEURAMINIDASE
Modality	Vaccine component
Phase	FDA-approved
First approval	2007

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results